Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated with few adverse events, consistent with previously reported studies ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announce ...

Financial Reporting - Supernus Pharmaceuticals, Inc. will report its Q4 and full year 2024 business results on February 25, 2025[4] - A conference call and webcast will be held on February 25, 2025, at 4:30 p.m. E.T. to discuss the financial results[4]

ROCKVILLE, Md., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2024 after the market closes on Tuesday, February 25, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a confe ...

Investors might want to bet on Supernus Pharmaceuticals (SUPN) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracke ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's diseaseONAPGO is a wearable subcutaneous infusion device that provides continuous treatment during the waking day for more consistent control of OFF timeONAPGO will be available in the U.S. in second quarter 2025 ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and com ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous infusion device that provides continuous treatment during the waking day for more consistent control of OFF timeONAPGO will be available in the U.S. in second quarter 2025 ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and co ...

Core Insights - Supernus Pharmaceuticals has received FDA approval for an updated label for Qelbree, which now includes new pharmacodynamic data and lactation information [1][2][3] Group 1: Product Information - Qelbree (viloxazine extended-release capsules) is approved for treating ADHD in patients aged 6 years and older [4] - The updated label highlights viloxazine's partial agonist activity at the serotonin 5-HT2C receptor and its inhibition of the norepinephrine transporter, emphasizing its multimodal pharmacodynamic profile [1][6] - New lactation data indicates low transfer of Qelbree into breastmilk, with estimated daily infant doses of viloxazine and its metabolite being 0.085 mg/kg and 0.00595 mg/kg, respectively [2] Group 2: Clinical Insights - The updated pharmacodynamic data enhances understanding of Qelbree's effects, aiding treatment decision-making for ADHD [2][3] - The lactation study involved 15 healthy lactating women and followed a multi-dose regimen of viloxazine [2] - The study results support that the transfer of viloxazine into breastmilk is low, although it did not evaluate effects on breastfed infants [2] Group 3: Company Commitment - Supernus Pharmaceuticals aims to empower healthcare providers and patients with updated information to make informed treatment decisions [3] - The company is dedicated to building evidence around Qelbree's use in the ADHD space [3]

Core Insights - Knight Therapeutics Inc. has submitted a New Drug Submission (NDS) for Qelbree® to Health Canada, marking a significant step in expanding its ADHD treatment portfolio [1][4] - Qelbree® is a novel nonstimulant medication for ADHD, already approved in the United States for patients aged 6 and older, with a growing market for non-stimulant ADHD treatments in Canada [2][4] Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focused on acquiring and commercializing pharmaceutical products for Canada and Latin America [6] - The company operates under various subsidiaries in Latin America, including United Medical, Biotoscana Farma, and Laboratorio LKM [6] Product Development - Qelbree® is currently undergoing multiple clinical trials, including studies on its effectiveness in combination with psychostimulants and its impact on preschool-age children and adults with ADHD [3][4] - The first clinical trial reported positive topline results in September 2023, while a second trial for preschool-age children began in March 2024 [3] Market Insights - The Canadian market for non-stimulant ADHD products was valued at $83.5 million in 2023, with a 10% growth in prescriptions compared to 2022 and a compound annual growth rate (CAGR) of 11% over the past four years [4] - ADHD affects approximately 5-9% of children and adolescents and 3-5% of adults, indicating a significant ongoing medical need for effective treatment options [5]

ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 9:30 a.m. GMT (4:30 a.m. EST) at the Waldorf Hilton in London, United Kingdo ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we are circling back to a small biopharma concern called Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) . We looked at this name in the first quarter of this year and noted ...